PRESS RELEASE published on 06/01/2025 at 19:15, 6 months 3 days ago Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050 Transgene and NEC reveal positive data on TG4050 cancer vaccine, demonstrating durable disease-free survival and sustained T cell responses at 24 months in HPV-negative head and neck cancer. Conference call on June 6, 2025 Cancer Vaccine Transgene TG4050 ASCO 2025 NEC
BRIEF published on 05/22/2025 at 17:50, 6 months 13 days ago Transgene to Present Phase I Data on Cancer Vaccine TG4050 at ASCO 2025 Cancer Vaccine Transgene TG4050 ASCO 2025 Phase I Data
PRESS RELEASE published on 05/22/2025 at 17:45, 6 months 13 days ago Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025 Transgene to present 24-month disease-free survival data from all patients in Phase I part of trial of individualized cancer vaccine, TG4050, at ASCO 2025 Cancer Vaccine Transgene TG4050 ASCO 2025 Disease-free Survival
BRIEF published on 04/10/2025 at 20:20, 7 months 24 days ago Transgene makes available the 2024 Universal Registration Document AMF Social Responsibility Immunotherapy Registration Document Transgene
PRESS RELEASE published on 04/10/2025 at 20:15, 7 months 24 days ago Availability of Transgene’s 2024 Universal Registration Document (URD) Transgene announces availability of its 2024 Universal Registration Document (URD) containing financial reports and ESG factors. French & English versions can be accessed online Financial Reports Transgene ESG Factors 2024 Universal Registration Document French Version
BRIEF published on 03/27/2025 at 17:50, 8 months 8 days ago Transgene: major advances and outlook for 2025 Immunotherapy Head And Neck Cancer 2024 Financial Results TG4050 Vaccine Myvac® Platform
PRESS RELEASE published on 03/27/2025 at 17:45, 8 months 8 days ago Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025 Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF published on 01/21/2025 at 17:50, 10 months 14 days ago Transgene Prepares for Biomed Investor Forum Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE published on 01/21/2025 at 17:45, 10 months 14 days ago Transgene to Participate in the Biomed Forum Investor Conference Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025 Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF published on 11/05/2024 at 07:35, 1 year 1 month ago Transgene and ProBioGen join forces for personalized cancer vaccines Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
Published on 12/05/2025 at 02:35, 6 hours 33 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 8 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 3 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 8 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 08:30, 38 minutes ago Dahua Technology Celebrates Pro Challenge 2025 to Deepen Global Installer Ecosystem Collaboration
Published on 12/05/2025 at 08:30, 38 minutes ago Premier Miton Global Renewables Trust PLC - Suspension
Published on 12/05/2025 at 08:05, 1 hour 3 minutes ago Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 1 hour 7 minutes ago Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 1 hour 7 minutes ago Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:45, 23 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 8 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 15 hours 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 15 hours 24 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health